FindTrial
Sign In

Study of the excess cost associated with the drug wasted due to limited options of the size of anti-cancer drug vials, among patients receiving such treatment at Tata Memorial Hospital

Study of the excess cost associated with drug wastage due to limited vial size options of the intravenous drugs for anti-cancer treatment, among patients receiving such treatment at Tata Memorial Hospital - CADWIACT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/08/027054
Enrollment
1240
Registered
2020-08-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

None listed

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Adult cancer patients The patients advised and receiving any of the following 62 chemotherapy protocols will be included in the study. Solid 1 AC Paclitaxel+-trastuzumab Gemcitabine+carboplatin EC TDM1 CMF Carboplatin+paclitaxel+/-Bevacizumab Liposomal doxorubin TCH(Docetaxel,carboplatin,trastuzumab) BEP EP EMACO EMA EP SA Dactinomycin SA Methotrexate mFOLFOX FOLFIRI Cape-OX Cap-Irinotecan SA Docetaxel Cetuximab Panitumumab Trastuzumab Ramucirumab Cape-Mitomycin FOLFIRINOX Gem-Oxaliplatin Gem+cisplatin DOF EOX DCF Gem+nab paclitaxel Solid 2 Pemetrexed+Cisplatin Pemetrexed+Carboplatin Pemetrexed-carboplatin+/- pembrolizumab Gemcitabine+carboplatin Paclitaxel+carboplatin Geftinib+bevacizumab Nivolumab Cisplatin+etoposide Carboplatin+etoposide SA Irinotecan SA Gemcitabine SA Paclitaxel SA Docetaxel BEP EP Gemcitabine+cisplatin Gemcitabine+carboplatin TIP Adult Hematology VCD VRD RDHAP RGDP RCHOP ABVD Bendamustine-rituximab FCR R EPOCH HiDAC CHOP RCEOP

Exclusion criteria

Exclusion criteria: patients aged < 18 years

Design outcomes

Primary

MeasureTime frame
To assess the excess costs in (INR) associated with left-over/unused drugs due to limited strength vial options.Timepoint: Six months—

Secondary

MeasureTime frame
suggest vial sizes to pharmaceutical companies per Indian requirements average, median and mode values of the prescribed dose by cancer types for IV anti-cancer drugs for patients at TMH association of socio-demographic characteristics with excess cost due to wasted drugs association of excess costs due to wasted anti-cancer drug with treatment non-compliance among patients at TMH proportion of leftover drug per disease and per drug at TMH potential number of patients treated/100 vials/drug Timepoint: Six months—

Countries

India

Contacts

Public ContactDr Amit Joshi

Tata Memorial Hospital

dramitjoshi74@gmail.com02224176229

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026